Clinical Efficacy of a 2-Week Treatment Course of Zuranolone for the Treatment of Major Depressive Disorder and Postpartum Depression: Outcomes From the Clinical Development Program
Introduction Antidepressants that offer a rapid onset of action without requiring chronic use are greatly needed in both major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational, oral, neuroactive steroid and GABAA receptor positive allosteric modulator in c...
Main Authors: | A. Clayton, A.J. Cutler, K.M. Deligiannidis, R. Lasser, A.J. Sankoh, J. Doherty, M. Kotecha |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2022-06-01
|
Series: | European Psychiatry |
Subjects: | |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822002826/type/journal_article |
Similar Items
-
Efficacy and tolerability of zuranolone in patients with depression: a meta-analysis of randomized controlled trials
by: Youjia Qiu, et al.
Published: (2024-01-01) -
Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analysesResearch in context
by: Yu-Wei Lin, et al.
Published: (2023-12-01) -
Efficacy and safety of zuranolone in the treatment of major depressive disorder: a meta-analysis
by: Shuyu Wang, et al.
Published: (2024-01-01) -
Zuranolone – synthetic neurosteroid in treatment of mental disorders: narrative review
by: Rafał Marecki, et al.
Published: (2023-12-01) -
Rapid improvements in MADRS with zuranolone in major depressive disorder and postpartum depression: results from the LANDSCAPE/NEST clinical development programmes
by: A. H. Clayton, et al.
Published: (2023-03-01)